A detailed history of Capital Counsel LLC transactions in Moderna, Inc. stock. As of the latest transaction made, Capital Counsel LLC holds 9,070 shares of MRNA stock, worth $363,979. This represents 0.03% of its overall portfolio holdings.

Number of Shares
9,070
Previous 9,070 -0.0%
Holding current value
$363,979
Previous $1.08 Million 43.73%
% of portfolio
0.03%
Previous 0.05%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$101.21 - $166.61 $91,089 - $149,949
-900 Reduced 9.03%
9,070 $1.08 Million
Q1 2024

May 15, 2024

SELL
$85.37 - $115.44 $36,794 - $49,754
-431 Reduced 4.14%
9,970 $1.06 Million
Q4 2023

Feb 14, 2024

SELL
$69.51 - $104.43 $11,816 - $17,753
-170 Reduced 1.61%
10,401 $1.03 Million
Q3 2023

Nov 13, 2023

BUY
$96.41 - $126.61 $226,852 - $297,913
2,353 Added 28.63%
10,571 $1.09 Million
Q1 2023

May 15, 2023

BUY
$135.66 - $197.02 $61,047 - $88,659
450 Added 5.79%
8,218 $1.26 Million
Q4 2022

Feb 09, 2023

BUY
$118.38 - $210.04 $2,485 - $4,410
21 Added 0.27%
7,768 $1.4 Million
Q3 2022

Nov 14, 2022

BUY
$118.07 - $194.18 $3,542 - $5,825
30 Added 0.39%
7,747 $916,000
Q2 2022

Aug 15, 2022

BUY
$117.13 - $176.59 $2,811 - $4,238
24 Added 0.31%
7,717 $1.1 Million
Q1 2022

May 16, 2022

SELL
$126.46 - $235.05 $758 - $1,410
-6 Reduced 0.08%
7,693 $1.33 Million
Q4 2021

Feb 14, 2022

SELL
$225.82 - $368.51 $20,549 - $33,534
-91 Reduced 1.17%
7,699 $1.96 Million
Q3 2021

Nov 12, 2021

SELL
$221.9 - $484.47 $11,095 - $24,223
-50 Reduced 0.64%
7,790 $3 Million
Q2 2021

Aug 12, 2021

SELL
$129.91 - $234.98 $23,383 - $42,296
-180 Reduced 2.24%
7,840 $1.84 Million
Q1 2021

May 12, 2021

BUY
$109.18 - $185.98 $875,623 - $1.49 Million
8,020 New
8,020 $1.05 Million

Others Institutions Holding MRNA

About Moderna, Inc.


  • Ticker MRNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 391,200,000
  • Market Cap $15.7B
  • Description
  • Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, resp...
More about MRNA
Track This Portfolio

Track Capital Counsel LLC Portfolio

Follow Capital Counsel LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Counsel LLC, based on Form 13F filings with the SEC.

News

Stay updated on Capital Counsel LLC with notifications on news.